Novo Nordisk doesn't feel threatened by GLP-1 rival Lilly
Novo Nordisk: Switch To Weekly Ozempic Has Begun, Biopharma M&A Sought :: Scrip
Novo Nordisk's insulin pen receives EU approval to treat type 2 diabetes
Novo Nordisk 2018: Struggling against the tide – PharmaLive
Novo Nordisk's Ozempic is quick out of the blocks, chasing Lilly's Trulicity - PMLiVE
Glucagon-Like Peptide-1 (Glp-1) Analogs Market will generate new growth opportunities 2022-2028 | Novo Nordisk, Eli-Lilly and Company | Medgadget
Novo's fast-launching Ozempic puts Lilly on notice—and its GLP-1 pill is on its way | Fierce Pharma
First Oral GLP-1 Receptor Agonist Approved for Type 2 Diabetes - MPR
Novo Nordisk 2022: Expanding capabilities – PharmaLive
FDA approves Novo Nordisk's semaglutide for weight management - Drug Discovery and Development
GLP-1 diabetes drugs are being released one after another
Novo Nordisk gains GLP-1 market share within and outside the US despite seeing new GLP-1 prescriptions curbed by COVID-19 - MidgardFinance.com
Novo Nordisk India launches GLP-1 RA, Oral Semaglutide for diabetes management, Health News, ET HealthWorld
Novo Nordisk readies new obesity treatment after Saxenda < Pharma < Article - KBR
Another Weight-Loss Trial Win for Weekly GLP-1 Drug | MedPage Today
Treatment with glucagon‐like peptide‐1 receptor agonists and incidence of dementia: Data from pooled double‐blind randomized controlled trials and nationwide disease and prescription registers - Nørgaard - 2022 - Alzheimer's & Dementia: Translational
Novo Nordisk comments on role of off-label use in Ozempic shortfall
The Now Generation & New Generation of GLP-1 RAs: Reshaping the Care of T2DM
GLP-1 franchise powers progress at Novo Nordisk in 2021
